Becht D, Selvam K, Lachance C, Cote V, Li K, Nguyen M
Nat Struct Mol Biol. 2025; .
PMID: 39794553
DOI: 10.1038/s41594-024-01455-8.
Guo Y, Li J, Zhang K
Front Mol Biosci. 2024; 11:1492212.
PMID: 39606030
PMC: 11599741.
DOI: 10.3389/fmolb.2024.1492212.
Zhou M, Cole P
Nat Rev Drug Discov. 2024; 24(2):112-133.
PMID: 39572658
PMC: 11798720.
DOI: 10.1038/s41573-024-01080-6.
Guo X, Atla S, Nyalata S, Alugubelli Y, Chen P, Xu S
J Med Chem. 2024; 67(22):20100-20117.
PMID: 39530508
PMC: 11613437.
DOI: 10.1021/acs.jmedchem.4c01337.
Janssens D, Duran M, Otto D, Wu W, Xu Y, Kirkey D
Nat Commun. 2024; 15(1):9341.
PMID: 39472576
PMC: 11522475.
DOI: 10.1038/s41467-024-53399-8.
Histone methyltransferase KMT2A: Developmental regulation to oncogenic transformation.
Ogino J, Dou Y
J Biol Chem. 2024; 300(10):107791.
PMID: 39303915
PMC: 11736124.
DOI: 10.1016/j.jbc.2024.107791.
A potent and selective ENL degrader suppresses oncogenic gene expression and leukemia progression.
Xue Z, Qin L, Xuan H, Luo K, Huang M, Xie L
Sci Adv. 2024; 10(35):eado1432.
PMID: 39196923
PMC: 11352836.
DOI: 10.1126/sciadv.ado1432.
Single-cell multiomics reveals ENL mutation perturbs kidney developmental trajectory by rewiring gene regulatory landscape.
Song L, Li Q, Xia L, Sahay A, Qiu Q, Li Y
Nat Commun. 2024; 15(1):5937.
PMID: 39009564
PMC: 11250843.
DOI: 10.1038/s41467-024-50171-w.
Pharmacological targeting of the cancer epigenome.
Mabe N, Perry J, Malone C, Stegmaier K
Nat Cancer. 2024; 5(6):844-865.
PMID: 38937652
DOI: 10.1038/s43018-024-00777-2.
Leveraging a Phage-Encoded Noncanonical Amino Acid: A Novel Pathway to Potent and Selective Epigenetic Reader Protein Inhibitors.
Chen P, Guo X, Zhang H, Dubey G, Geng Z, Fierke C
ACS Cent Sci. 2024; 10(4):782-792.
PMID: 38680566
PMC: 11046469.
DOI: 10.1021/acscentsci.3c01419.
Lead Optimization of Small Molecule ENL YEATS Inhibitors to Enable Studies: Discovery of TDI-11055.
Michino M, Khan T, Miller M, Fukase Y, Vendome J, Adura C
ACS Med Chem Lett. 2024; 15(4):524-532.
PMID: 38628784
PMC: 11017412.
DOI: 10.1021/acsmedchemlett.4c00016.
The C-terminal protein interaction domain of the chromatin reader Yaf9 is critical for pathogenesis of .
Lo T, Wang Q, Nickson J, van Denderen B, Deveson Lucas D, Chai H
mSphere. 2024; 9(3):e0069623.
PMID: 38376217
PMC: 10964406.
DOI: 10.1128/msphere.00696-23.
Histone Readers and Their Roles in Cancer.
Wen H, Shi X
Cancer Treat Res. 2023; 190:245-272.
PMID: 38113004
PMC: 11395558.
DOI: 10.1007/978-3-031-45654-1_8.
Small-molecule tools for YEATS domain proteins.
Erb M
Curr Opin Chem Biol. 2023; 77:102404.
PMID: 37924571
PMC: 10842393.
DOI: 10.1016/j.cbpa.2023.102404.
MOZ/ENL complex is a recruiting factor of leukemic AF10 fusion proteins.
Komata Y, Kanai A, Maeda T, Inaba T, Yokoyama A
Nat Commun. 2023; 14(1):1979.
PMID: 37031220
PMC: 10082848.
DOI: 10.1038/s41467-023-37712-5.
A novel bis-triazole scaffold accessed via two tandem [3 + 2] cycloaddition events including an uncatalyzed, room temperature azide-alkyne click reaction.
Malkova K, Bubyrev A, Krivovicheva V, Darin D, Bunev A, Krasavin M
Beilstein J Org Chem. 2022; 18:1636-1641.
PMID: 36530536
PMC: 9727270.
DOI: 10.3762/bjoc.18.175.
Evaluation of acyllysine isostere interactions with the aromatic pocket of the AF9 YEATS domain.
Travis C, Francis D, Williams Jr D, Waters M
Protein Sci. 2022; 32(1):e4533.
PMID: 36482045
PMC: 9793969.
DOI: 10.1002/pro.4533.
TAZ/YAP fusion proteins: mechanistic insights and therapeutic opportunities.
Garcia K, Gingras A, Harvey K, Tanas M
Trends Cancer. 2022; 8(12):1033-1045.
PMID: 36096997
PMC: 9671862.
DOI: 10.1016/j.trecan.2022.08.002.
Small-Molecule Inhibition of the Acyl-Lysine Reader ENL as a Strategy against Acute Myeloid Leukemia.
Liu Y, Li Q, Alikarami F, Barrett D, Mahdavi L, Li H
Cancer Discov. 2022; 12(11):2684-2709.
PMID: 36053276
PMC: 9627135.
DOI: 10.1158/2159-8290.CD-21-1307.
Fragment-Based Discovery of AF9 YEATS Domain Inhibitors.
Liu Y, Jin R, Lu H, Bian K, Wang R, Wang L
Int J Mol Sci. 2022; 23(7).
PMID: 35409252
PMC: 8998803.
DOI: 10.3390/ijms23073893.